Novo Nordisk stock is coming off a weak patch over the past three years, yet current valuation checks and an intrinsic value estimate suggest the market price may still sit well below what its cash flows imply.

• The share price has declined 33.4% over the last three years, which raises the question of whether expectations have reset too far relative to the company’s fundamentals.
• Recent EU approval for oral and higher dose injectable Wegovy can support long term revenue and cash flow expectations, while the lawsuit with Eli Lilly over GLP 1 advertising may add some legal and reputational uncertainty to those expectations.
• Novo Nordisk screens as undervalued on most checks, with the company passing 5 of 6 valuation tests. This points to a broader picture that leans cheap rather than fully priced based on this valuation summary.

The issue now is whether that apparent discount to intrinsic value gives Novo Nordisk enough margin of safety for investors at today’s price.

Is Novo Nordisk Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Novo Nordisk is worth today based on the cash it can generate in the future. On this view, the company is currently producing last twelve month free cash flow of about DKK 48.2b and the projection set assumes that cash flows continue to grow from this base rather than shrink.

Using those growing cash flows, the DCF model arrives at an estimated intrinsic value of about $96 per share. Compared with the current share price, this implies the stock trades at roughly a 47.2% discount, which points to Novo Nordisk appearing undervalued on this cash flow view. Because the recent EU approval of both oral and higher dose injectable Wegovy supports expectations for ongoing cash generation, the gap between price and intrinsic value remains notable.

On this DCF assessment, Novo Nordisk stock currently appears undervalued relative to its estimated intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 47.2%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Is Novo Nordisk a Bargain on Earnings?

The P/E ratio suits Novo Nordisk because earnings are the key yardstick many investors use for large, established pharmaceutical stocks. Novo Nordisk currently trades on a P/E of about 12.2x, which is below both the pharmaceuticals industry average of 15.5x and a wider peer average of 26.0x. That comparison suggests the stock is not priced at a premium despite its scale and established product portfolio.

A more tailored benchmark for Novo Nordisk is the modelled fair P/E of about 23.0x, which reflects its earnings profile, margins, size and risk factors. Relative to this measure, the current 12.2x multiple indicates a sizeable discount rather than a fully priced stock. On this market multiple view, Novo Nordisk appears inexpensive compared with what investors might typically pay for similar earnings.

On the P/E yardstick, Novo Nordisk stock screens as undervalued compared with both the sector and its modelled fair multiple.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Novo Nordisk's valuation checks leave off. They spell out which paths for Novo Nordisk's growth, margins and earnings would need to play out for the stock to be worth much more or much less than today’s price, and they sit on the company’s Community page. Each narrative links its number to a clear view on how growth, profitability and risks might evolve, which you can then revisit as new information comes through.

One of the top community narratives on Novo Nordisk: 46% undervalued

"Current sentiment has swung deeply negative, but expectations are now low, and the market appears to assign little to no value to Novo’s development-stage pipeline…"

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

The Bottom Line

Novo Nordisk screens as undervalued on both the Discounted Cash Flow (DCF) view and the current P/E multiple, so the market is pricing in a fair amount of caution already. The key question is whether cash flows and earnings can keep supporting that intrinsic value estimate in the face of legal and competitive pressures around GLP 1 treatments. For you, the crux is whether the current discount reflects an opportunity or is the market’s way of pricing in those risks. Your stance on that trade off is what will drive any decision from here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.